Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Some claims are consistent with the provided COSENTYX label excerpts (notably infection risk counseling, hypersensitivity/serious allergy guidance, immunization/live vaccine caution, and immune response/immune system effects). Several claims are only broadly stated (inflammatory conditions/immune mechanism) or omit label-specific evaluation/administration details; a key counseling nuance about pausing/discontinuation is overstated as clinician action without matching the label wording. Drug interaction and boxed warning alignment cannot be fully assessed from the provided label text.
Category Scores
Accurate Statements
Cosentyx (secukinumab) can affect the immune system.
Label Warnings 5.7 (Immunizations: COSENTYX may alter immune response to live vaccines) and Pharmacodynamics 12.2 (COSENTYX may alter immune response to live vaccines).
Cosentyx may cause common and less common reactions.
Label 6 Adverse Reactions includes clinical trials infections (common) and broader adverse reaction reporting in 6.1/6.2 (e.g., serious infections/opportunistic infections and postmarketing reactions).
Patients are advised to report infections or symptoms that could signal an allergic reaction while taking Cosentyx.
Label Warnings 5.1 (Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur) and Warnings 5.2 (hypersensitivity reactions; discontinue and initiate appropriate therapy for anaphylactic/serious allergic reaction).
Cosentyx treatment safety may be affected by current infections, recent vaccines, past allergic reactions, and history of conditions that raise infection risk.
Label Warnings 5.1 (exercise caution in chronic/recurrent infection; serious infection management) and 5.2 (hypersensitivity) and 5.7 (consider completion of age-appropriate immunizations; avoid live vaccines; COSENTYX may alter immune response to live vaccines).
Certain symptoms (e.g., fever, cough, painful urination, or skin changes) may change whether treatment with Cosentyx should be started or paused.
Partial support: Label 5.1 advises seeking medical advice for signs/symptoms suggestive of infection; label 5.3 requires TB evaluation prior to initiation; label 5.5 notes eczematous eruptions onset variable and treatment may need discontinuation to resolve. (The claim’s generic 'start or paused' framing is not label-specific.)
If side effects occur after starting Cosentyx, a doctor may pause therapy, switch treatment, or treat the symptoms directly depending on the side effect and its severity.
Partial support: Label 5.1 (serious infection: monitor closely and discontinue until infection resolves) and 5.2 (immediately discontinue for anaphylactic/serious allergic reaction) and 5.5 (treatment may need to be discontinued to resolve eczematous eruption).
Patients should not stop Cosentyx on their own without medical guidance.
Partial support via label management language: Label 5.1 (discontinue only after developing serious infection; monitor closely) and 5.2 (immediately discontinue if serious hypersensitivity occurs). (The provided excerpts do not explicitly state the patient 'should not stop on their own' wording.)
Symptoms of the underlying disease being treated with Cosentyx can overlap with medication side effects.
Not directly supported in the provided excerpts; however, overlap is not explicitly addressed. (No label support located in provided text.)
A full list of Cosentyx side effects can be reviewed via prescribing information and patient-facing safety summaries.
Supported generally only by the existence of adverse reactions in label sections 6.1/6.2. The specific mention of 'patient-facing safety summaries' is not supported in the provided label excerpts.
Unsupported Statements
Cosentyx is used for inflammatory conditions.
The provided label excerpts do not state indications; 'inflammatory conditions' is too nonspecific and not directly supported by the included sections.
Cosentyx works by changing immune activity.
Label excerpts provided discuss immune response to live vaccines (12.2/5.7) and 'immune system disorders' as adverse reactions, but do not explicitly describe mechanism as 'changing immune activity' in that form.
Symptoms of the underlying disease being treated with Cosentyx can overlap with medication side effects.
No such overlap guidance is present in the provided excerpts.
Clinicians typically want a clear description of when symptoms started and how they feel to distinguish disease symptoms from Cosentyx side effects.
No such clinician documentation guidance is present in the provided excerpts.
Clinicians typically assess for infection-type signs (e.g., fever, chills, worsening cough) when distinguishing disease symptoms from Cosentyx side effects.
While the label instructs patients to seek medical advice if infection signs/symptoms occur (5.1), it does not provide this specific 'distinguish disease vs medication side effects' workflow or list examples like 'chills/worsening cough' in that context.
A full list of Cosentyx side effects can be reviewed via prescribing information and patient-facing safety summaries.
Prescribing information support is partial, but 'patient-facing safety summaries' is not mentioned in the provided label excerpts.
Contradictions
Low
AI Statement
Cosentyx treatment safety may be affected by current infections, recent vaccines, past allergic reactions, and history of conditions that raise infection risk.
Label Reference
No direct contradiction found in provided excerpts; evaluation is partial support only.
Important Omissions
TB pre-treatment evaluation (active or latent TB) and avoidance in active TB; initiate treatment of latent TB prior to COSENTYX; monitor for TB during/after treatment.
Importance:
Moderate
Live vaccine avoidance (avoid use of live vaccines during treatment) and immunization completion considerations prior to initiating therapy.
Importance:
Moderate
Specific administration route limitations: UnoReady pen, Sensoready pen, and prefilled syringes are for subcutaneous use only; solution in vials is for IV use in adult patients only.
Importance:
Moderate
Drug interaction counseling regarding concomitant CYP450 substrates (monitor therapeutic effect/concentration and adjust dosage as needed upon initiation/discontinuation).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Safety-related counseling is partially aligned (infection seeking advice and hypersensitivity management concepts). However, several claims are generic and omit label-specific pre-treatment and management details (TB evaluation, live vaccine avoidance, administration route restrictions), which could reduce adherence to label-specified safety steps.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Multiple claims are either too nonspecific to verify against the provided label excerpts (e.g., indications/immune mechanism) or include counseling details not present in the excerpts (disease-vs-side-effect differentiation). Key label-specific safety steps (TB screening, live vaccine guidance, administration route, and CYP450 interaction monitoring) are omitted.
Suggested Improvement
Rephrase to match label language in the provided sections: emphasize infection counseling and discontinuation/management for serious infections and hypersensitivity; include TB evaluation and latent TB treatment prior to initiation; include avoiding live vaccines and completing immunizations beforehand; add administration route constraints and mention CYP450 substrate monitoring/possible dosage adjustment.